Clinical trials · Boston, MA
Breast Cancer Invasive clinical trials in Boston
We’re tracking 50 recruiting breast cancer invasive studies with a site in or near Boston — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Boston
- NCT04230109RecruitingTeam says not enrollingPhase 2
Sacituzumab Govitecan for newly diagnosed TNBC
This trial tests a drug called sacituzumab govitecan for people with newly diagnosed triple-negative breast cancer (TNBC) that hasn't been treated yet. The drug targets cancer cells directly to try to stop them from growing.
Boston, MassachusettsAges 18 years+ - NCT05232916RecruitingPhase 3
Vaccine for HER2-positive breast cancer after standard treatment
This trial tests a vaccine (GLSI-100) that may help prevent the return of HER2-positive breast cancer. It is given to patients who still had cancer cells after initial treatment with trastuzumab, or who had stage III disease and achieved a complete response.
Boston, MassachusettsAges 18–100 - NCT05879926RecruitingPhase 3
Testing chemo after hormone therapy in premenopausal early breast cancer
This Phase 3 trial checks whether adding chemotherapy after standard hormone-blocking treatment works better for some premenopausal women with early-stage, ER-positive, HER2-negative breast cancer. It targets patients with limited lymph node spread and a lower-to-intermediate tumor “recurrence” risk score.
Boston, MassachusettsAges 18–60 - NCT06923527RecruitingPhase 2
Testing ctDNA to start elacestrant in early breast cancer
This trial tests whether the drug elacestrant can help prevent recurrence in people with a type of breast cancer (ER+/HER2-) who have finished hormone therapy and have signs of cancer DNA in their blood (ctDNA positive) but no visible spread on scans.
Boston, MassachusettsAges 18 years+ - NCT05929768RecruitingPhase 3
Shorter chemo plus immunotherapy without anthracyclines for early TNBC
This Phase 3 trial tests whether a shorter course of chemotherapy plus immunotherapy can work as well as standard treatment for early-stage triple-negative breast cancer. It avoids anthracycline drugs and may help reduce exposure to those medicines if the shorter plan is effective and safe.
Boston, MassachusettsAges 18 years+ - NCT06998407RecruitingPhase 1/Phase 2
Study of AVZO-023 for advanced solid tumors
This trial tests a new drug, AVZO-023, alone or with other treatments, for people with advanced solid tumors that have not responded to standard therapy. The goal is to see if it can shrink tumors or slow their growth.
Boston, MassachusettsAges 18 years+ - NCT06896474Recruiting
Breast cancer treatment choice help for women 70 and older
This study tests a decision aid to help women 70 and older with early stage breast cancer choose their treatment. It looks at whether the tool helps patients and their doctors make a confident treatment choice.
Boston, MassachusettsAges 18 years+ - NCT06099769RecruitingPhase 2
Testing enzalutamide with or without mifepristone for AR-positive breast cancer
This trial tests if adding the drug mifepristone to the standard antiandrogen enzalutamide works better than enzalutamide alone or chemotherapy for people with a specific type of breast cancer that has androgen receptors. It aims to find a new targeted treatment option for triple-negative or ER-low breast cancer.
Boston, MassachusettsAges 18 years+ - NCT05812807RecruitingPhase 3
Pembrolizumab versus monitoring after triple-negative breast cancer response
This trial checks whether giving pembrolizumab (an immunotherapy) after surgery helps people with triple-negative breast cancer reduce the chance of the cancer coming back, compared with close monitoring only. It’s for patients who had no remaining invasive cancer after neoadjuvant chemotherapy plus pembrolizumab.
Boston, MassachusettsAges 18 years+ - NCT04368702Recruiting
MRI-guided radiation for people needing radiation for cancer
This study tests whether radiation given with help from MRI (a type of scan) can better treat cancers that need radiation. You may be eligible if your cancer is confirmed and you can safely have MRI scans.
Boston, MassachusettsAges 18 years+ - NCT06492616RecruitingPhase 3
Elacestrant vs standard hormone therapy for high-risk early breast cancer
This trial tests a new hormone therapy pill (elacestrant) against standard hormone therapy for people with a common type of early breast cancer (ER+, HER2-) that has a higher chance of returning. You may qualify if you've already been on hormone therapy for 2 to 5 years and want to see if a different pill works better.
Boston, MassachusettsAges 18 years+ - NCT07000084RecruitingPhase 3
Testing gemcitabine with BCG for returning bladder cancer
This trial tests whether adding a chemotherapy drug called gemcitabine to the usual BCG therapy can help prevent bladder cancer from coming back again. If you have had BCG before and your cancer returned, this study might offer a more effective treatment option.
Boston, MassachusettsAges 18 years+ - NCT07222215RecruitingPhase 2
Capacitabine with or without elacestrant for ER+ breast cancer
This trial tests if adding a new oral targeted therapy (elacestrant) to standard chemotherapy (capecitabine) works better than chemotherapy alone for people with a specific type of advanced breast cancer that is hormone-sensitive (ER-positive) and has stopped responding to hormone therapy.
Boston, MassachusettsAges 18 years+ - NCT06827613RecruitingPhase 1/Phase 2
Study of invikafusp alfa plus sacituzumab govitecan for advanced solid tumors
This trial tests a new drug combination for people with advanced breast cancer (triple-negative or hormone receptor-positive). The goal is to see if the combination helps shrink tumors or slow their growth.
Boston, MassachusettsAges 18 years+ - NCT06533826RecruitingPhase 2
Testing two antibody drugs for HER2-low breast cancer
This trial tests two antibody-drug conjugates (Enhertu and Datroway) for breast cancer that is HER2-low or HER2-0. It aims to find the best treatment sequence for people whose cancer has stopped responding to prior therapy.
Boston, MassachusettsAges 18 years+ - NCT06184750RecruitingPhase 2
Finding the best tamoxifen dose to lower breast cancer risk
This trial tests different doses of tamoxifen to find the best one for lowering breast cancer risk in premenopausal women. It aims to see if a lower dose works as well as the standard dose with fewer side effects.
Boston, MassachusettsAges 18–55 - NCT06876714RecruitingPhase 3
Shorter vs Longer HER2 Therapy for Breast Cancer with Complete Response
This trial compares 6 months versus 12 months of HER2-targeted therapy for people with HER2+ breast cancer who had a complete response after chemo and trastuzumab. The goal is to see if a shorter treatment is just as effective.
Boston, MassachusettsAges 18 years+ - NCT02290834Recruiting
Studying brain and thinking changes after chemotherapy in older breast cancer patients
This study looks at how chemotherapy may affect memory and thinking, using thinking tests and possibly brain imaging. It compares older breast cancer patients who do and do not get chemotherapy, plus a group of healthy older adults.
Boston, MassachusettsAges 60 years+ - NCT06439693RecruitingPhase 2
Sequential therapy for newly diagnosed HER2+ breast cancer that has spread
This trial tests a sequence of targeted therapies for people newly diagnosed with HER2-positive breast cancer that has spread to other parts of the body. The goal is to find a treatment plan that can potentially cure the cancer.
Boston, MassachusettsAges 18 years+ - NCT06451497RecruitingPhase 1
Testing ZM008 alone and with toripalimab for advanced cancers
This trial tests a new drug called ZM008, which targets a protein on some cancer cells, first alone and then combined with another drug, toripalimab, for people with advanced solid tumors that have stopped responding to standard treatments.
Boston, MassachusettsAges 18 years+ - NCT05795101RecruitingPhase 2
TRUDI trial for inflammatory breast cancer with HER2/low markers
This Phase 2 trial tests two medicines—durvalumab and trastuzumab deruxtecan—to treat stage III inflammatory breast cancer. It may help by controlling cancer growth using treatments aimed at specific breast cancer markers (HER2 positive or “HER2-low”).
Boston, MassachusettsAges 18 years+ - NCT07123649RecruitingPhase 2
Customizing mammogram schedules for older breast cancer survivors
This study looks at how often older breast cancer survivors (80+) should get mammograms. It aims to make screening more personalized so women get the right amount of imaging.
Boston, MassachusettsAges 80 years+ - NCT05467891RecruitingPhase 2
Ribociclib plus hormone therapy for recurrent breast cancer
This trial tests whether adding ribociclib (a targeted pill) to hormone therapy can control breast cancer that has come back in the breast area or nearby lymph nodes/chest wall. It targets hormone-receptor–positive and HER2-negative tumors to help slow disease after local treatment.
Boston, MassachusettsAges 18 years+ - NCT07061964RecruitingPhase 2
Immunotherapy and radiation to save the bladder
This trial tests whether combining immunotherapy and low-dose radiation after chemotherapy can help you avoid bladder removal. It's for people whose muscle-invasive bladder cancer has shrunk significantly after initial treatment.
Boston, MassachusettsAges 18 years+
Hear when a new Breast Cancer Invasive trial opens near Boston, MA
We’ll email you when one opens near Boston, MA — at most once a week, no account needed, unsubscribe anytime.
Where these studies are running near Boston
Institutions with a site for the recruiting breast cancer invasive studies listed above.
- Dana-Farber Cancer Institute · 17 studies
- Beth Israel Deaconess Medical Center · 7 studies
- Brigham and Women's Hospital · 5 studies
- Lahey Hospital and Medical Center · 5 studies
- Massachusetts General Hospital · 5 studies
- Lahey Medical Center-Peabody · 4 studies
- Rhode Island Hospital · 4 studies
- Solinsky Center for Cancer Care · 4 studies
What taking part in a breast cancer invasive study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting breast cancer invasive studies in Massachusetts.
Common questions
- Are there breast cancer invasive clinical trials near Boston?
- Yes. We're currently tracking 50 recruiting breast cancer invasive studies with a site near Boston, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a breast cancer invasive study near Boston?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Boston to take part?
- Not necessarily. These studies have a site near Boston, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a breast cancer invasive trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New breast cancer invasive studies open near Boston regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.